mCRPC – Talk Bio

Actionable Insights Powered by AI

FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo

2 weeks ago talkbio0Tagged Advisory Committees, enzalutamide, expansion, Inhibitor, Labels (device), Malignant neoplasm of prostate, mCRPC, PARP1 gene, Pfizer, talazoparib, Talzenna, unanimous vote, United States Food and Drug Administration

FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote

Lava cuts jobs by 30% after key drug discontinued

3 months ago talkbio0Tagged cash runway, Discontinuation (procedure), LAVA, LAVA-1266, mCRPC, restructuring, strategic alternatives

LAVA Therapeutics, restructuring, workforce reduction, LAVA-1207, discontinuation, mCRPC, LAVA-1266, strategic alternatives, cash runway